KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)R&D In ProcessShares IssuedShares Repurchased
Ratios

Vertex Pharmaceuticals (VRTX) Accumulated Depreciation & Amortization: 2009-2024

  • Vertex Pharmaceuticals' Accumulated Depreciation & Amortization fell 10.44% to $1.1 billion in Q4 2024 from the same period last year, while for Dec 2024 it was $4.2 billion, marking a year-over-year increase of 7.03%. This contributed to the annual value of $1.1 billion for FY2024, which is 10.44% down from last year.
  • Latest data reveals that Vertex Pharmaceuticals reported Accumulated Depreciation & Amortization of $1.1 billion as of Q4 2024, which was down 10.44% from $1.2 billion recorded in Q4 2023.
  • Vertex Pharmaceuticals' 5-year Accumulated Depreciation & Amortization high stood at $1.2 billion for Q4 2023, and its period low was $790.6 million during Q4 2020.
  • Moreover, its 3-year median value for Accumulated Depreciation & Amortization was $1.1 billion (2024), whereas its average is $1.1 billion.
  • Per our database at Business Quant, Vertex Pharmaceuticals' Accumulated Depreciation & Amortization increased by 15.73% in 2023 and then fell by 10.44% in 2024.
  • Quarterly analysis of 5 years shows Vertex Pharmaceuticals' Accumulated Depreciation & Amortization stood at $790.6 million in 2020, then grew by 13.33% to $896.0 million in 2021, then rose by 14.65% to $1.0 billion in 2022, then climbed by 15.73% to $1.2 billion in 2023, then fell by 10.44% to $1.1 billion in 2024.
  • Its last three reported values are $1.1 billion in Q4 2024, $1.2 billion for Q4 2023, and $1.0 billion during Q4 2022.